Cover Image
Market Research Report

Cardiac Rhythm Management (CRM) Devices Market, (By Product (Pacemakers, Cardiac Resynchronization Therapy (CRT), and Defibrillators); By Region): Market Size & Forecast, 2018 - 2026

Published by Polaris Market Research Product code 873247
Published Content info 117 Pages
Delivery time: 1-2 business days
Price
Back to Top
Cardiac Rhythm Management (CRM) Devices Market, (By Product (Pacemakers, Cardiac Resynchronization Therapy (CRT), and Defibrillators); By Region): Market Size & Forecast, 2018 - 2026
Published: October 1, 2018 Content info: 117 Pages
Description

The global Cardiac Rhythm Management (CRM) Devices Market is anticipated to reach USD 33.0 Billion by 2026 according to a new research published by Polaris Market Research. The cardiac rhythm management devices include external as well as implantable devices to manage and treat cardiac disorder. Precisely designed implantable devices for tasks either to fasten cardiac rhythm (cardioverter defibrillators) or to slow down heart rhythm (pacemakers) has proven to benefit patients as their overall health status can be improved. Such device is used to deliver therapeutic solutions to people suffering from cardiac ailments such as cardiac arrhythmias, cardiac arrests, or heart failure.

The global Cardiac Rhythm Management (CRM) Devices market is majorly driven by the continuous efforts by key market players of product launch and approval majorly in emerging and underdeveloped economies. For instance, Boston Scientific Corporation is planning to get a regulatory approval for its S-ICD system across Middle East, and Africa and Asia Pacific. The private and government sector establishments have attempted to provide favorable reimbursement outlines for cardiac disorders treatment in developing and underdeveloped economies. Moreover, the key players have collaborated with government organizations to provide innovative as well as effective cardiac solutions. The increase in approvals for technologically advanced devices, growing disposable incomes, and inclination in the awareness regarding welfare associated with such devices are expected to further enhance the market growth during the forecast period.

Geographically, North America region accounted for the largest share in the global Cardiac Rhythm Management (CRM) Devices Market during 2017 owing to favorable reimbursement schemes, developed healthcare infrastructure, higher healthcare expenditure, and increasing awareness among the population. Moreover, Asia Pacific region is anticipated to generative lucrative opportunities for the Cardiac Rhythm Management (CRM) Devices Market during the forecast period. Increasing penetration of health insurance in emerging economies such as China and India are expected to be one of the major reasons for the growth of this market.

The leading companies profiled in the Cardiac Rhythm Management (CRM) Devices Market report include Abiomed, Inc., Berlin Heart GmbH, Biotronik SE & Co. KG, Boston Scientific Corporation, Cardiac Science Corporation, General Electric Company (GE), Hill-Rom Holdings, Inc., Koninklijke Philips N.V., LivaNova PLC, Medtronic plc, SCHILLER AG and Abbott Laboratories. These companies launch new products and collaborate with other market leaders to innovate and to meet the increasing needs and requirements of consumers.

Table of Contents
Product Code: PM1529

Table of Contents

1. Overview and Scope

  • 1.1. Research goal & scope
  • 1.2. Research assumptions
  • 1.3. Research Methodology
    • 1.3.1. Primary data sources
    • 1.3.2. Secondary data sources
  • 1.4. Key take-away
  • 1.5. Stakeholders

2. Executive Summary

  • 2.1. Market Definition
  • 2.2. Market Segmentation

3. Cardiac Rhythm Management (CRM) Devices Market Insights

  • 3.1. Cardiac Rhythm Management (CRM) Devices - Industry snapshot
  • 3.2. Cardiac Rhythm Management (CRM) Devices - Ecosystem analysis
  • 3.3. Cardiac Rhythm Management (CRM) Devices Market Dynamics
    • 3.3.1. Cardiac Rhythm Management (CRM) Devices - Market Forces
      • 3.3.1.1. Cardiac Rhythm Management (CRM) Devices Market Driver Analysis
      • 3.3.1.2. Cardiac Rhythm Management (CRM) Devices Market Restraint/Challenges analysis
      • 3.3.1.3. Cardiac Rhythm Management (CRM) Devices Market Opportunity Analysis
  • 3.4. Industry analysis - Porter's five force
    • 3.4.1. Bargaining power of supplier
    • 3.4.2. Bargaining power of buyer
    • 3.4.3. Threat of substitute
    • 3.4.4. Threat of new entrant
    • 3.4.5. Degree of competition
  • 3.5. Cardiac Rhythm Management (CRM) Devices Market PEST Analysis, 2017
  • 3.6. Cardiac Rhythm Management (CRM) Devices Market Value Chain Analysis
  • 3.7. Cardiac Rhythm Management (CRM) Devices Industry Trends
  • 3.8. Competitive Ranking Analysis

4. Cardiac Rhythm Management (CRM) Devices Market Size and Forecast, 2017-2026 by Product

  • 4.1. Key Findings
  • 4.2. Pacemakers
    • 4.2.1. Implantable Pacemakers
    • 4.2.2. External Pacemakers
  • 4.3. Defibrillators
    • 4.3.1. Implantable Cardioverter Defibrillators (ICDs)
      • 4.3.1.1. Subcutaneous ICD (S-ICD)
      • 4.3.1.2. Transvenous ICD (T-ICD)
    • 4.3.2. External Defibrillator (ED)
      • 4.3.2.1. Manual ED
      • 4.3.2.2. Automated ED (AED)
      • 4.3.2.3. Wearable Cardioverter Defibrillator
  • 4.4. Cardiac Resynchronization Therapy (CRT)
    • 4.4.1. CRT-Defibrillators (CRT-D)
    • 4.4.2. CRT-Pacemakers (CRT-P)

5. Cardiac Rhythm Management (CRM) Devices Market Size and Forecast, 2017-2026 by Region

  • 5.1. Key Findings
  • 5.2. North America
    • 5.2.1. U.S.
    • 5.2.2. Canada
  • 5.3. Europe
    • 5.3.1. Germany
    • 5.3.2. UK
    • 5.3.3. France
  • 5.4. Asia-Pacific
    • 5.4.1. China
    • 5.4.2. India
    • 5.4.3. Japan
  • 5.5. Latin America
    • 5.5.1. Brazil
  • 5.6. Middle East & Africa

6. Company Profiles

  • 6.1. Abiomed, Inc.
    • 6.1.1. Overview
    • 6.1.2. Financials
    • 6.1.3. Product Benchmarking
    • 6.1.4. Recent Developments
  • 6.2. Berlin Heart GmbH
    • 6.2.1. Overview
    • 6.2.2. Financials
    • 6.2.3. Product Benchmarking
    • 6.2.4. Recent Developments
  • 6.3. Biotronik SE & Co. KG
    • 6.3.1. Overview
    • 6.3.2. Financials
    • 6.3.3. Product Benchmarking
    • 6.3.4. Recent Developments
  • 6.4. Boston Scientific Corporation
    • 6.4.1. Overview
    • 6.4.2. Financials
    • 6.4.3. Product Benchmarking
    • 6.4.4. Recent Developments
  • 6.5. Cardiac Science Corporation
    • 6.5.1. Overview
    • 6.5.2. Financials
    • 6.5.3. Product Benchmarking
    • 6.5.4. Recent Developments
  • 6.6. General Electric (GE) Company
    • 6.6.1. Overview
    • 6.6.2. Financials
    • 6.6.3. Product Benchmarking
    • 6.6.4. Recent Developments
  • 6.7. Hill-Rom Holdings, Inc.
    • 6.7.1. Overview
    • 6.7.2. Financials
    • 6.7.3. Product Benchmarking
    • 6.7.4. Recent Developments
  • 6.8. Koninklijke Philips N.V.
    • 6.8.1. Overview
    • 6.8.2. Financials
    • 6.8.3. Product Benchmarking
    • 6.8.4. Recent Developments
  • 6.9. LivaNova PLC
    • 6.9.1. Overview
    • 6.9.2. Financials
    • 6.9.3. Product Benchmarking
    • 6.9.4. Recent Developments
  • 6.10. Medtronic plc
    • 6.10.1. Overview
    • 6.10.2. Financials
    • 6.10.3. Product Benchmarking
    • 6.10.4. Recent Developments
  • 6.11. SCHILLER AG
    • 6.11.1. Overview
    • 6.11.2. Financials
    • 6.11.3. Product Benchmarking
    • 6.11.4. Recent Developments
  • 6.12. Abbott Laboratories
    • 6.12.1. Overview
    • 6.12.2. Financials
    • 6.12.3. Product Benchmarking
    • 6.12.4. Recent Developments
Back to Top